PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.
Evidence
Gene Expression assays to tailor adjuvant endocrine therapy
Clinical Cancer Research OF1–OF11, May 2024 Author: Bottosso et al.
Read MoreCost Effectiveness of MammaPrint in Brazil
The Breast 76 (2024) 103752 Author: Mansani et al.
Read MoreImproved Neoadjuvant Chemo Prediction for HR+HER2- ESBC with MP High 2
21st Bossche Mamma Congress 2024, P07 Presenter: O'Shaughnessy et al.
Read MoreElucidating the immune active state of HR+HER2- MammaPrint High 2
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer
Read MoreMammaPrint 3-year outcomes with CT with/without anthracycline
ASCO 2024, #511 Presenter: O'Shaughnessy et al.
Read MoreNeoadjuvant CT Recommendations in Black women – SSO 2024
SSO 2024 Author: Solis-Pomales et al.
Read MoreNeoadjuvant Endocrine Treatment outcomes – The Breast 2024
The Breast 75 (2024) 103726 Presenter: van Olmen et al.
Read More
